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Over the last decades, life expectancy has significantly increased although several 
chronic diseases persist in the population, with aging as the leading risk factor. Despite 
improvements in diagnosis and treatment, many elderlies suffer from cardiovascular 
problems that are much more frequent in an older, more fragile organism. In the long 
term, age-related cardiovascular diseases (CVDs) contribute to the decline of quality of 
life and ability to perform normal activities of daily living. microRNAs (miRNAs) are a class 
of small non-coding RNAs that regulate gene expression at the posttranscriptional level 
in both physiological and pathological conditions. In this review, we will focus on the role 
of miRNAs in aging and age-related CVDs as heart failure, hypertension, atherosclerosis, 
atrial fibrillation, and diabetes mellitus. miRNAs are key regulators of complex biological 
mechanisms, representing an exciting potential therapeutic target in CVDs. Moreover, 
one major challenge in geriatric medicine is to find reliable biomarkers for diagnosis, 
prognosis, and prediction of the response to specific drugs. miRNAs represent a very 
promising tool due to their stability in the circulation and unique signature in CVDs. 
However, further studies are needed to investigate their translational potential in the real 
clinical practice.
Keywords: microRNA, aging, cardiovascular diseases, heart failure, atherosclerosis, hypertension, diabetes, atrial 
fibrillation
iNTRODUCTiON
Cardiovascular diseases (CVDs) in older patients inflict a huge burden in terms of mortality and 
morbidity, contributing to disability and decline of quality of life (1–3). In addition, aging itself 
produces numerous changes in human heart, at structural, molecular, and functional levels. The 
most important age-related alterations are left ventricular (LV) hypertrophy, fibrosis, denervation, 
and maladaptive remodeling that frequently lead to diastolic dysfunction (4–7). Vascular aging is 
characterized by impaired endothelial function, chronic vascular inflammation, and augmented 
arterial stiffness (8). Endothelial dysfunction is mainly related to increased production of reac-
tive oxygen species (ROS) partially due to an increased activity of NAD(P)H oxidases (NOX) (9). 
Moreover, increased age-related oxidative stress and decreased production of nitric oxide (NO) 
FiGURe 1 | The canonical microRNA (miRNA) pathway. pri-miRNA are transcribed by RNA polymerase II or III (RNA pol II/III) and then processed by Drosha/
DiGeorge syndrome critical region gene 8 (DGCR8) into pre-miRNA transcripts. Pre-miRNAs are exported from the nucleus via exportin-5 (Exp 5) to cytoplasm 
where processed by Dicer/TAR RNA-binding protein (TRBP), which generates double-stranded RNAs (miRNA duplex). Argonaute proteins 1–4 (Ago 1–4) unwind 
and then separate the guide strand (miRNA) and the passenger strand (miRNA passenger). The RNA-induced silencing complex (RISC) incorporates the mature 
miRNA and regulates gene expression by translation repression or mRNA degradation.
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constitute critical factors for the alteration of cardiovascular (CV) 
homeostasis (10). microRNAs (miRNAs) are small non-coding 
RNAs approximately 18–25 nucleotides long, which regulate 
gene expression at different levels. Importantly, miRNAs are 
emerging as key factors in the development and progression 
of CVDs. Notably several basic and clinical studies identified 
peculiar  miRNAs expression profile in pathological conditions. 
Consequently, miRNA have been proposed as diagnostic/prog-
nostic biomarkers and therapeutic targets.
The present article will focus on the regulation and function 
of miRNAs in CV aging and age-related CVDs as heart failure 




microRNAs constitute a class of small non-coding RNAs that 
regulate gene expression at the posttranscriptional level in both 
physiological and pathological conditions. miRNAs are highly 
conserved during evolution with a well-established role in cell pro-
liferation, differentiation, metabolism, apoptosis, development, 
and aging as well as in the pathophysiology of many diseases such 
as cancer, CVDs, and neurological disorders (11). The miRNA 
coding regions are mainly present in the genome as clusters (12). 
The classical miRNA production is called “the canonical pathway” 
(Figure 1). Essentially, miRNAs are transcribed in the nucleus by 
the RNA polymerase II (or in few cases RNA polymerase III) as 
a pri-miRNA. pri-miRNA represents a primary long transcript 
(>1 kb) bearing a hairpin-shaped structure that provisionally dis-
plays a 5′-Cap and a 3′-poly(A) tail (13–15). pri-miRNAs are then 
cleaved into around 70-nucleotide pre-miRNAs by the micropro-
cessor complex that contains Drosha (a RNAse III enzyme) and its 
cofactor DiGeorge syndrome critical region gene 8 (DGCR8) (13, 
16). The pre-miRNAs are subsequently exported to the cytoplasm 
by exportin-5, via a RAN-GTP-dependent mechanism, where 
they are processed into 20–25 nucleotide double-stranded-RNAs 
(miRNA duplex) by Dicer (another RNAse III enzyme) and by 
its cofactor TAR RNA-binding protein (13). In the cytoplasm, 
miRNA duplex is finally separated into two RNA strands, the guide 
RNA strand (miRNA) and the passenger RNA strand (miRNA 
passenger) that is generally degraded. The miRNA is then bound 
by Argonaute proteins 1–4 and loaded into the RNA-induced 
silencing complex in order to influence the target mRNA expres-
sion (13). The miRNA target sites, known as miRNA recognition 
elements, are frequently located in the 3′-untranslated region of 
the mRNA. It has been also described that miRNAs can bind to the 
5′-untranslated region or to the open reading frame (13, 17, 18). 
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miRNAs can repress gene target by either mRNA decay or transla-
tion repression (19). Interestingly, it has been reported that some 
miRNA bypass particular maturation steps of the canonical 
miRNA pathway and follow an alternative miRNA biogenesis 
(13): some authors showed the biogenesis of specific miRNA to 
be Dicer-independent, while other miRNAs do not need Drosha/
DGCR8 for their maturation (so-called Mirtron pathway) (13). 
Recently, a third pathway (Agotron pathway) escapes both Drosha 
and Dicer processing and seems to limit off-target effects (13). The 
nomenclature of miRNA is indicated into the miRNA register and 
identifying numbers have been assigned serially (20–23).
Identical miRNAs have the same number, regardless of the 
specie. The pre-miRNA is referred as “mir-,” while a capitalized 
“miR-” suggests the mature form. The “mir” or “miR” are followed 
by a dash and a number (e.g., mir-22 or miR-22). Pre-miRNAs 
producing an identical mature miRNAs but positioned at differ-
ent places in the genome are labeled with an additional dash-
number suffix (e.g., mir-33-1 and mir-33-2 lead to an identical 
mature miRNA, miR-33). Different mature miRNAs with almost 
identical sequences except for one or two nucleotides are marked 
with an additional lower case letter (e.g., miR-29a is strictly 
related to miR-29b). Two different mature miRNA strands that 
are cleaved from opposite arms of the same miRNA duplex 
have been conventionally designated for example as miR-75-5p 
(5′ arm) and miR-75-3p (3′ arm). However, relative expression 
levels are frequently known and an asterisk following the name 
indicates an miRNA expressed at low levels relative to the one in 
the opposite arm of a hairpin (low expressed miRNA has been 
previously indicated as RNA passenger): for example, miR-21 and 
miR-21* (20–24).
Biomarkers and Therapeutic Options
The possibility to detect different miRNAs in numerous body 
fluids (blood, saliva, urine, etc.) opens up the opportunity to use 
these molecules as biomarker for age-related CVDs. Importantly, 
miRNAs are simply quantified by real-time polymerase 
chain reaction or microarrays and a combination of multiple 
miRNAs have been shown to provide a more sensitive and spe-
cific information (25–27). Serum and plasma miRNAs are prob-
ably the most suitable source for clinical application as sample 
collection is quick, simple, and reproducible. Indeed, miRNAs 
are remarkably stable and resistant in the blood and long-term 
storage or freezing/thawing cycles do not seem to cause problems 
(28, 29). Interestingly, circulating miRNAs are protected from 
endogenous high levels of RNase activity in the blood since they 
are linked to carriers in vesicles or non-vesicular forms (30). 
The non-vesicular forms account for 80–99% of total circulat-
ing miRNAs, which are linked to RNA-binding proteins in very 
stable complexes (Ago2-family proteins or nuclephosmine 1), or 
to lipoproteins as high-density lipoproteins (HDLs) (31–34). In 
addition, miRNAs can be integrated into extracellular vesicles 
such as exosomes, microvesicles, and apoptotic bodies (34). These 
microvesicles are secreted from the cell and involved in the com-
munication between cells through transfer of genetic informa-
tion. Exosomes (30–150 nm) are produced via inward budding 
of endosomal membranes that merge with the plasma membrane 
and then release their content into the extracellular environment 
as vesicles (34–37). On the contrary, microvesicles are larger 
(50–1,000 nm) vesicles generated by outward budding and fission 
from the cell surface, while apoptotic bodies (50  nm to 5  µm) 
result from cells during the late stages of apoptosis (34, 38, 39). 
Of note, Ago2 influences the function of secreted miRNAs in 
origin cell-secreted microvesicles (but not in recipient cells) (40).
In the last decade, miRNA-based therapeutics are emerging as 
promising and effective treatments.
Compared to current drugs, miRNA-based therapies target 
several genes that are under the control of the specific miRNA. 
miRNAs can be manipulated through replacement by specific 
oligonucleotides (miR-mimics) or inhibited by single-stranded 
antisense oligonucleotides (antimiRs or antagomirs) (24, 41). The 
miR-mimics are used in case of disease-related downregulation of 
a specific miRNA and are usually synthetized as double-stranded 
miRNA oligonucleotides that, when transfected into cells, are 
processed into a single-strand form and regulate target genes 
(42, 43). On the contrary, antagomiRs are modified antisense 
oligonucleotides that can inhibit the levels of upregulated miR-
NAs, thus increasing the expression of mRNAs targeted by that 
specific miRNA (42–44). The proposed routes of in vivo delivery 
of miRNA therapeutics to target CV system are intravenous, 
subcutaneous, intramuscular, intraperitoneal, cardiac, or transc-
oronary but it is still unclear which one among them is the most 
effective. However, since local delivery is particularly desirable 
for the miRNA-based treatment, cardiac or intracoronary injec-
tions probably represent an optimal choice in case of heart disease 
(HF due to different etiologies or age-related heart dysfunction) 
(41, 45, 46). The main delivery strategies/technologies for 
miRNA therapeutics include lipid-based vehicles, viral systems, 
biodegradable scaffolds, “exosome-encapsulated” miRNAs, or 
light-induced antagomir activation (46–48).
miRNAs iN CARDiOvASCULAR AGiNG
miRNAs in Cardiac Aging
Physiological cardiac aging is associated with an increase in car-
diac fibrosis, LV hypertrophy, valvular degeneration, and mainly 
diastolic dysfunction (4).
Numerous miRNAs have been described to be differently 
expressed and to regulate different cell types and pathways dur-
ing cardiac aging (see Table 1) (49, 50). Zhang et al. showed that 
cardiac miR-21 is upregulated with age (50). miR-21 profibrotic 
effect is induced via ERK–MAP kinase pathway activation in 
cardiac fibroblasts (CFs) during injury (see below) (51).
In addition, overexpression of Ago1 and Ago2 synergistically 
induced miR-21 and miR-21*, suggesting a regulatory role for 
Ago proteins (50).
Another miRNA involved in cardiac aging is miR-22 (52). 
Age-related miR-22 upregulation contributed to accelerate CF 
senescence and increased migration (52). The effects of miR-22 in 
CFs were mediated by the proteoglycan mimecan/osteoglycin (52). 
miR-22 regulatory sequence deletion in Mimecan gene was able to 
revert in part the effects of miR-22, recommending Mimecan as a 
potential target (52). Interestingly, Mimecan/osteoglycin has been 
previously shown to regulate arteriogenesis, collagen fibrillogen-
esis in the extracellular matrix (ECM), and cardiac hypertrophy 
TABLe 1 | Summarizing table of microRNAs (miRNAs) involved in cardiac and vascular aging.
Tissue miRNA Molecular targets Functions Reference
Aging heart miR-21 ↑ ERK–MAP kinase signaling Profibrotic [role on cardiac fibroblast (CFs)] (51)
Aging heart miR-22 ↑ Mimecan/Osteoglycin Accelerate CF senescence and migration (52)
Aging heart miR-18 and 
miR-19 ↓
Thrombospondin-1 and connective 
tissue growth factor
Anti-heart failure-related fibrosis during aging (58)
Aging heart miR-17-3p ↓ PAR-4 Reduce CF cellular senescence (61)
Aging heart miR-34a ↑ Phosphatase 1 nuclear targeting 
subunit
Increase age-related cardiomyocyte apoptosis and cardiac dysfunction (62)
Vascular aging miR-34a ↑ SIRT1 Stimulates senescence in endothelial cell and vascular smooth muscle cells (68, 71)
Vascular aging miR-217 ↑ SIRT1 Stimulates endothelial senescence decreasing nitric oxide (73)
Vascular aging miR-29 ↑ Collagen and elastin Extracellular matrix impairment (risk of age-related aortic aneurism) (74–77)
Vascular aging miR-146 ↑ or ↓ IRAK and NOX4 Pro-inflammation or anti-oxidative stress (78, 79)
Vascular aging miR-92 ↓ Tumor necrosis factor α receptor 1 
and collagen type 1
miR-92 reduction mimic arterial aging (80)
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(see below) (53–55). Moreover, Gupta et al. have recently suggested 
a role for miR-22 in aged cardiomyocytes (56). The inhibition of 
miR-22 stimulated cardiac autophagy, curbed maladaptive remod-
eling, and enhanced cardiac function post-myocardial infarction 
(MI) in older mice, but not in younger ones (56). On the other 
hand, a recent integromics network meta-analysis indicates that 
miR-22 does not importantly impact on heart longevity when 
compared to other age-modified miRNAs (57). miR-17-92 cluster 
has been widely shown to be involved in cardiac aging and consists 
of six mature miRNAs: miR-17, miR-18a, miR-19a, miR-19b, miR-
20a, and miR-92a. van Almen et al. found that miR-18 and miR-19 
levels were decreased in an aged HF-prone mouse strain when 
compared to age-matched controls (58, 59). These findings were 
also confirmed in human samples, and this is crucial since HF is a 
frequent comorbidity in elderly patients (58, 60).
miR-18 and miR-19 downregulation in the heart was associated 
with increased levels of connective tissue growth factor (CTGF) 
and thrombospondin-1, fundamental in the remodeling of the 
ECM. Importantly, the authors demonstrated that this pathway 
is specific for cardiomyocytes (rather than CFs) and influences 
collagen production (58).
miR-17-3p has been shown to reduce cardiac aging and CF 
cellular senescence by targeting Par4, instead (61).
Remarkably, miR-34a expression was significantly augmented 
in aged human hearts, in a mouse model of accelerated aging or 
post-MI (62). The latter finding suggests miR-34a to constitute 
a promising candidate for the treatment of elderly patient suf-
fering from postischemic HF. In fact, the inhibition of miR-34a 
through gene deletion or antagomiR was able to reverse both 
postischemic and age-related cardiac dysfunction. The authors 
showed anti-miR-34a therapy to reduce cardiomyocyte cell death 
via phosphatase 1 nuclear targeting subunit and regulation of 
telomere length (62).
miRNAs in vascular Aging
Vascular aging is characterized by endothelial dysfunction, 
increased fibrosis, and arterial stiffness (63). The wall of large 
arteries, particularly the aorta, is thicker and less elastic during 
aging, mainly due to progressive deterioration and loss of elastin 
together with increase in collagen fibers (64, 65). In addition, 
hypertension and atherosclerosis are extremely frequent in the 
elderly population and substantially contribute to biomechanical 
and structural alterations of the vascular system (see below for 
specific miRNA involved in pathophysiology of hypertension and 
atherosclerosis) (66). On the other hand, increased aortic stiffness 
has been recently associated with higher risk of incident hyperten-
sion (67).
Numerous studies have evaluated the role of miRNAs during 
aging in cell models of vascular senescence or in vessels isolated 
from animal models of physiological aging (Table 1).
miR-34a has been shown to be upregulated in senescent 
endothelial cells (ECs) and vascular smooth muscle cells 
(VSMCs) as well as in cultured endothelial progenitor cells and 
bone marrow-derived pro-angiogenic cells from elderly patients 
with coronary artery disease (CAD) or from mouse model of 
physiological aging (68–71). miR-34a main target is SIRT1, a 
histone deacetylase representing both a longevity-stimulating 
enzyme and an important component for endothelial function 
via Notch signaling (68, 72). Similar to miR-34, miR-217 has been 
shown to be overexpressed in human umbilical vein endothelial 
cells (HUVECs) and to downregulate SIRT1. In addition, miR-
217 upregulation determined higher acetylation of SIRT-1 target 
genes like FoxO1 and endothelial nitric oxide synthase (eNOS) 
(73). miR-29 family members (miR-29a, miR-29b, and miR-29c) 
are upregulated in the aorta of aged mice and decreased levels 
of collagens and elastin, crucial ECM components (74, 75). 
Importantly, miR-29a was significantly augmented in cultured 
senescent ECs, suggesting their involvement in the phenomenon 
(75). Furthermore, an antagomiR directed to miR-29 increased 
ECM proteins expression in Angiotensin II (Ang II)-induced 
aneurysm model aged mice, as well as in genetic models of tho-
racic aortic aneurysm formation; this evidence even confirmed 
the relevance of this miRNA in vivo (74–77). The role of miR-146 
is controversial: some authors found miR-146 to be upregulated 
TABLe 2 | Summarizing table of main effects of different microRNAs (miRNAs) 
reported in the text within specific cardiac remodeling characteristics.
miRNA Cardiac remodeling 
implication
effect Reference
miR-1 Cardiomyocyte hypertrophy Anti-hypertrophic (108)
Cardiomyocyte apoptosis Pro-apoptosis (126)
miR-15a Cardiomyocyte apoptosis Pro-apoptosis (128)
miR-15b Cardiomyocyte apoptosis Pro-apoptosis (128)
miR-21 Cardiac fibrosis Profibrotic (130)
miR-22 Cardiomyocyte hypertrophy Pro-hypertrophic (115)
miR-23a Cardiomyocyte hypertrophy Pro-hypertrophic (117)
miR-24 Cardiac fibrosis Antifibrotic (133)
miR-29 Cardiac fibrosis Antifibrotic (135)
miR-30 Cardiomyocyte apoptosis Anti-apoptosis (123)
Cardiac fibrosis Antifibrotic (136)
miR-130 Cardiac fibrosis Antifibrotic (136)
miR-132 Cardiomyocyte hypertrophy Pro-hypertrophic (118)
miR-133a Cardiomyocyte hypertrophy Anti-hypertrophic (112)
miR-199a Cardiomyocyte apoptosis Anti-apoptosis (125)
miR-208a Cardiomyocyte hypertrophy Pro-hypertrophic (119)
miR-212 Cardiomyocyte hypertrophy Pro-hypertrophic (118)
miR-320 Cardiomyocyte apoptosis Pro-apoptosis (127)
miR-378 Cardiomyocyte hypertrophy Anti-hypertrophic (114)
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in cellular model of endothelial senescence, otherwise another 
group reported its downregulatation. In the first study, miR-146 
upregulation in ECs was related to reduced IRAK levels (a pro-
tein involved in the inflammatory response) while in the second 
one its induced overexpression favorably lowered NOX4 levels 
(78, 79). Consequently, in vivo studies are necessary to determine 
the role of miR-146a during vascular aging.
miR-92a is reduced both in arteries of older adults and mouse 
model of vascular aging (80). miR-92a inhibition (through an 
antagomiR) in young mice showed a phenotype similar to the 
one typical of arterial aging via tumor necrosis factor α recep-
tor 1 and collagen type 1 upregulation. However, in order to 
determine the real efficacy of miR-92a in vivo, it is necessary to 
evaluate if its upregulation is able to revert age-related vascular 
dysfunction.
Circulating miRNAs during Aging
microRNAs are secreted in the extracellular space and are emerg-
ing as important molecules for paracrine and systemic com-
munication between different cells, organs, and systems. Thus, a 
combination of specific circulating miRNAs would be a valuable 
tool to estimate the age-related deterioration of different organs.
Currently, geriatricians are using numerous clinical multidi-
mensional indexes to identify frail elderly patients and to predict 
the risk of mortality (81, 82). In fact, multidimensional scales 
usually evaluate medical comorbidities, psychosocial behavior, 
and functional capabilities of elderlies in order to quantify 
overall health during aging (83–85). Despite several studies have 
been performed, current multidimensional instruments are not 
adequate to extensively stratify the risk for hospitalization and 
mortality in old people since influenced by different comorbidi-
ties and factors. Indeed, a considerable limit of these frailty scales 
is that different tools have been shown to be only effective in spe-
cific clinical conditions or settings (e.g., HF, cancer, or dementia; 
population-level frailty screening versus clinical screening) and, 
so far, no assessment scale is applicable to every elderly patient 
(83, 84, 86, 87).
Therefore, to add new circulating biomarkers as circulating 
miRNAs to current geriatric tools would be definitely valuable. 
Circulating miRNAs have potential uses for the diagnosis and 
prognosis of many age-related CVDs; their levels have been 
correlated with different ages and some of them have been 
associated with successful aging (see below). At this regard, it 
has been shown that aging per  se influences circulating levels 
of some miRNAs in animal models of physiological aging as 
well in elderly subjects compared to younger (88–90). Victoria 
and colleagues performed a network analysis of circulating 
miRNAs and found that miR-34b/c and miR-449 expression 
levels correlated with age (88). This finding is not surprising 
since miR-34 family members (miR-34a, -34b, and -34c) have 
already been associated with cardiac dysfunction as well as 
Alzheimer’s disease both in animal models and humans (91, 92). 
Moreover, Victoria et al. showed that plasma levels of miR-146a, 
already associated with endothelial senescence (see above), 
rises in aged normal mice, but was unchanged in dwarf mice 
that have increased life span (88, 89). In addition, many studies 
found a different circulating miRNA profile in centenarians 
(“extraordinary successful aging”) compared to septuagenarians 
(“ordinary aging”) (90, 93). Circulating levels of miR-21-5p 
increase during aging and strictly relate to a longevity pheno-
type (downregulated in successful aging compared to ordinary 
aging) (90, 94–96). Interestingly, cardiac miR-21 has been also 
shown to be increased in a mouse model of aging (Table 1) (50). 
However, increased levels of circulating miR-21 in aged patients 
would be almost partially due to its connection with MI/age-
related cardiac dysfunction and cancer, frequent comorbidities 
in elderly (50, 97, 98). Remarkably, miR-181 was downregulated 
in peripheral blood of older subject and further reduced in age-
matched patients with HF (99).
miRNAs iN HeART FAiLURe
Heart failure is a clinical syndrome characterized by a decline in 
contractile function, activation of several neurohormonal mecha-
nisms, and cardiac remodeling. Although initially constituting an 
adaptive process to maintain cardiac output, LV remodeling plays 
a fundamental role in the progression to HF and is characterized by 
cardiomyocytes hypertrophy, apoptosis, and excessive myocardial 
fibrosis (100). Several signaling pathways and systems, such as 
sympathetic nervous system (SNS), renin–angiotensin–aldoster-
one system (RAAS), and inflammatory pathway, involved in the 
pathogenesis of HF, have been widely studied (101–103). Incidence 
and prevalence of HF increase with aging, and exacerbation of HF 
is one of the leading causes of hospitalization among over 65 years 
older people (104). Recently, multiple publications have reported 
relevant implications of tissue and circulating mRNAs in cardiac 
function, in specific processes of cardiac remodeling and also in 
the prognosis of MI (summary in Table 2) (105, 106).
In this paragraph, we discuss the role of miRNAs in car-
diomyocyte hypertrophy, cardiac cells apoptosis, cardiac fibrosis, 
and circulating miRNAs.
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miRNAs in Cardiomyocytes Hypertrophy
Initially, Zhao et al. reported that miR-1 targets are genes involved 
in cardiac muscle differentiation and their excessive expression 
leads to decreased cardiomyocytes proliferation (107). In a mouse 
model of aortic constriction-induced hypertrophy, cardiac miR-
NAs expression profile obtained by microarray RNA analysis 
showed that miR-1 was downregulated since the early phase after 
cardiac hypertrophy induction. Moreover, in  vitro overexpres-
sion of miR-1 reduced the levels of growth-related factors as 
fibronectin, Ras homolog enriched in brain, GTPase-activating 
protein, and cyclin-dependent kinase-9 (108). miR-1 action has 
been reported to be mediated by calmodulin, calcineurin, and 
nuclear factor of activating T cells (NFAT) (109).
Activation of insulin growth factor-1 receptor (IGF-R1), 
P13K/Akt pathway, and inhibition of anti-hypertrophic tran-
scriptional factor FOXO have been referred as the principal 
mechanisms involved in cardiac hypertrophy induced by miR-1 
inhibition (110). Similarly, cardiac samples from patients with 
hypertrophic cardiomyopathy or mitral stenosis were character-
ized by decreased miR-1 expression (111).
Interestingly, suppression of miR-133 was associated with a 
more pronounced cardiac hypertrophy (112). In addition to the 
main calcineurin/NFAT mechanism of action, miR-133 seems 
to act through the inhibition of α1-adrenergic receptor (113). 
Several in vivo experimental models of cardiac hypertrophy (pres-
sure overload, volume overload or isoproterenol pumps infusion) 
showed reduced expression of miR-378 (about 40–60%). In vitro 
overexpression of miR-378 prevented the development of cardiac 
hypertrophy (114). miR-378 downregulates the expression of 
IGF-R1, PI3K, and Akt. Xu et  al. found that in a rat model of 
cardiac hypertrophy, the most upregulated miRNA was miR-22. 
Furthermore, this study reported that miR-22 regulates the 
fetal gene expression (atrial natriuretic peptide and α-myosin 
heavy chain) and has an important influence in increasing car-
diomyocytes size, partly through targeting phosphate and tensin 
homolog (PTEN) (115). Overexpression of miR-27b in mice may 
induce cardiac hypertrophy targeting cardiomyocyte peroxisome 
proliferator-activated receptor-γ (116). Several studies reported 
that miR-23a, -212, and -132 mediate cardiac hypertrophy via 
FOXO3 downregulation (117, 118). Callis and colleagues found 
that overexpression of miR-208a induced cardiac hypertrophy, 
reduced the expression of thyroid hormone-associated protein 1 
and myostatin, 2, and importantly influenced electric conduction 
resulting in arrhythmias in mice (119). Furthermore, miR-208a 
was reported among miRNAs able to predict time-dependent 
cardiomyocyte hypertrophy and other characteristics of cardiac 
remodeling in endomyocardial biopsies from patients with 
dilated cardiomyopathy after β-blocker treatment (120).
miRNAs in Cardiac Cells Apoptosis
miR-21 overexpression in neonatal cardiomyocytes provides a 
protective role against oxidative-cell induced apoptosis, mediated 
by NF-κB targeting PTEN/AKT pathway (121, 122).
A reduction in miR-30 expression together with an increase in 
p53 expression was observed in rat cardiomyocytes in response to 
apoptotic stimulation. Interestingly, miR-30 regulates the activity 
of dynamin-related protein-1, a mitochondrial fission protein 
and the consequent suppression of p53 (123). Furthermore, it 
has been reported that miRNA-30 regulates the β-adrenergic 
signaling, targeting β1 and β2 adrenoceptors and G protein αi 
subunit (Giα2) in doxorobucin-induced myocardial injury (124). 
Suppression of p53 was also reported as an apoptotic cell effect 
of miR-199a under hypoxic conditions (125). Overexpression 
of miR-1 increased cardiac apoptosis in ischemia/reperfusion 
(I/R) mouse model (126). Mir-320 expression was significantly 
decreased in I/R model. Overexpression of this miRNA promoted 
cardiomyocytes apoptosis in  vitro and increased infarct size 
in vivo via heat shock protein 20 downregulation (127).
miR-15a and miR-15b were upregulated in postischemic 
HF models, with a more pronounced miR-15b implication. 
Overexpression of miR-15b led to loss of mitochondrial mem-
brane potential, while its inhibition increased expression levels 
of the Bcl-2 protein, suppressed the release of mitochondrial 
cytochrome c to the cytosol, and decreased the activities of cas-
pase-3 and -9 (128). Another miRNA with anti-apoptotic effect is 
miR-92a. It has been reported that the beneficial hypoxia/reoxy-
genation effect of miR-92a inhibition is mediated by Smad7 (129).
miRNAs in Cardiac Fibrosis
Several miRNAs have been identified as important regulators of 
CFs functioning. Initially, it was revealed that miR-21 expres-
sion is increased in CFs isolated from HF samples, augmenting 
ERK-MAP kinase activity through inhibition of sprout protein 
homolog 1 (SPRY1) and increased levels of fibroblasts growth fac-
tor (51). In situ studies reported that miR-21 expression is specific 
for the infarcted myocardium where collagen expression is high 
and CFs are the most present cell type. In addition, mir-21 regu-
lates the activity of metalloprotease 2 (MMP-2) through PTEN 
pathway. MMP-2 is well known for its role in ECM turnover, 
enhancing collagen deposition (130). Similarly, in LV biopsies 
from patients with severe aortic stenosis, miR-21 expression was 
significantly higher and correlated either with transvalvular mean 
gradient and collagen expression (131). The overexpression of 
miR-21 in CF cultures promoted signal transducer and activator 
of transcription 3 phosphorylation, increased CF proliferation, 
and profibrotic gene expression (132).
Other experiments performed on MI animal models identi-
fied miR-24 as a key regulator of postischemic HF. Importantly, 
miR-24 overexpression reduced levels of TGFβ, resulting in 
modulation of CFs proliferation and migratory properties (133).
In different experimental models of HF, miR-29 expression 
was highly downregulated within the infarcted area. Modulation 
of the expression of miRNA-29 regulates collagen production in 
CFs cell culture (134). CFs behavior in HF is also characterized 
by their transdifferentiation to a myofibroblast phenotype with 
enhanced migratory and proliferatory properties. Indeed, it has 
been reported that miR-29 is able to inhibit the fibrogenic differ-
entiation of fibroblasts mediated by TGF-beta (TGF-β)–Smad3 
signaling (135).
In CFs isolated by human LV hypertrophy and in animal 
models of HF, expression of miRNA-30 and -133 was inversely 
correlated to CTGF, a promoter of collagen synthesis by CFs. 
Overexpression of either miR-30 and -133 resulted in the reduc-
tion of CTGF and as expected collagen production (136).
TABLe 3 | Summarizing table of microRNAs (miRNAs) involved in hypertension.
Tissue miRNA Molecular targets Functions Reference
Kidney miR-181a and miR-663 Renin Renin–angiotensin–aldosterone system (RAAS)  
pathways regulation
(152, 153)
Vascular smooth muscle 
cells (VSMCs)
miR-483-3p Angiotensin-converting enzyme-1 (ACE-1), 
ACE-2, AT2R, AGT
RAAS pathways regulation (158)
VSMCs miR-143/145 ACE, angiotensin II type I receptor (AT1R) Modulates VSMCs phenotype (downregulation  
causes shift to synthetic phenotype)
(154, 155)




Endothelial nitric oxide synthase (eNOS)
Decreases: vascular inflammation,  




ECs miR-122 SLC7A1 Decreases nitric oxide production (166, 167)
ECs miR-221/222 eNOS
Ets-1
Stimulates vascular inflammation (162)
Plasma and exosomes miR-130a, miR-195, and 
miR-92a








Multiple targets, some involved in VSMCs 
biology
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Circulating miRNAs in Heart Failure
Although circulating miRNAs mainly originate from ECs 
and hematopoietic cells, circulating miRNAs of myocardial 
origin reflect changes of myocardial tissue miRNAs (137). 
Ovchinnikova et  al. described that circulating miR-18a-5p, 
-26b-5p, -27a-3p, -30e-5p, -106a-5p, -199a-3p, -652-3p, and 
-199a-3p were significantly decreased in patients with acute HF 
compared to healthy controls or patients affected by chronic HF. 
Importantly, a further decrease of these miRNA levels within 
48  h after the hospital admission for acute HF was associated 
with an increased risk of 6  months mortality (138). A study 
conducted in a population of ischemic and non-ischemic dila-
tive cardiomyopathy reported that circulating miR-125b and 
-497 were significantly decrease in ischemic patients, while 
miR-142-3b and -29b were increased in non-ischemic patients 
(139). Qiang and collaborators found that miR-126 and -508-5p 
may predict CV mortality among HF patients (140). Another 
study described the role of circulating miRNAs in the differential 
diagnosis of dyspnea in patients with symptomatic HF and in 
those with dyspnea of non-HF origin. Only miR-423-5p was 
significantly increased in patients with dyspnea of cardiac origin 
(141). A translational pilot study reported that in myocardial 
areas of dyssynchrony miR-30d expression was increased as a 
protective mechanism. Furthermore, plasma baseline level of 
this miRNA is associated with response to resynchronization 
therapy (142). Left ventricular assist devices (LVAD) implanta-
tion is emerging as a crucial treatment for end-stage HF patients, 
interestingly, appearing to determine a good survival rate in 
elderly patients (143). LVAD implantation is characterized by 
significant decrease in pulmonary pressure, reduction of circu-
lation time, and neurohormonal changes. Morley-Smith et  al. 
revealed that decreased miR-483-3p and -1202 myocardial and 
circulating expression was associated with successful response to 
LVAD implantation (144).
miRNAs iN HYPeRTeNSiON
Hypertension represents one of the most common diseases in 
adults and a leading risk factor for CVDs and kidney failure (145). 
Almost 29% of the worldwide population present high blood 
pressure (BP), and statistics show that this number is intended to 
growth reaching 1.5 billion by 2025 (145). The risk of developing 
high BP increases with age: 90% of not hypertensive 55-year-old 
subjects will develop this pathology later in life (146). Despite 
the fact that many drugs and changes in lifestyle have shown to 
decrease BP, currently just 50% of the hypertensive patients are 
responsive to treatment (147).
Blood pressure is regulated by an ensemble of cardiac, renal, 
vascular, and neurohormonal mechanisms (148). The patho-
genesis of hypertension is complex, involving ECs and VSMCs 
dysfunction, altered activation of RAAS and SNS together with 
increase in oxidative stress and inflammation (149). Several ani-
mal and human studies indicate that miRNAs contribute to the 
regulation of these aforementioned mechanisms, representing a 
new promising potential target for therapies. Moreover, circulat-
ing miRNAs are emerging as effective biomarkers in essential 
hypertension as discussed more in depth below (150).
The RAAS system has a pivotal role in the pathogenesis of 
hypertension (148). Its persistent and pathological activation can 
lead to alteration in BP, cardiac contractility, electrolyte balance, as 
well as vascular resistance and tone (151). Several studies indicate 
miRNAs to be intrinsically connected with all the components of 
this hormonal system (summary in Table 3).
Enhanced renin production, characteristic feature of geneti-
cally hypertensive mice (BPH/2J), is mediated at least in part by 
mechanisms involving miR-181a downregulation (152). Genetic 
expression profile performed on human hypertensive kidneys 
identified 11 miRNAs differentially expressed in comparison 
with normotensive kidneys. Among them, miR-663 and miR181a 
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levels were significantly lower in hypertensive patients and have 
been shown to directly bind renin mRNA (153). Angiotensin-
converting enzyme (ACE) catalyzes the conversion of Angiotensin 
I (Ang I) in its bioactive form Ang II, the main effector of RAAS. 
ACE is a target of miR-143/145 cluster. Expression of this cluster 
was increased by shear stress in ECs via activation of AMPK-p53 
pathway, leading to a reduction in ACE gene expression (154). 
Moreover, miRNA143/145 expression was fundamental to main-
tain the contractile phenotype of VSMCs in vitro and a regular 
BP in vivo. Loss of miR-143/145 led to an ACE enzyme overex-
pression and a shift from contractile to synthetic phenotype of 
VSMCs, which increased the probability to develop neointimal 
lesions (155). Synthetic VSMCs are characterized by increased 
proliferation and migration ability. These cells sustain the vas-
cular remodeling occurring during hypertension (156). Using a 
model of balloon-induced vascular wall injury in rats, two studies 
showed that, besides miR-143/145, also miR-21 and mir-221/222 
are regulators of VSCMs aberrant proliferation and neointimal 
hyperplasia (97).
Angiotensin II directly influences ECs and VSCMs growth, 
phenotype, and migration. In addition, Ang II regulates 
expression of vasoactive molecules, hormones, ECM proteins 
in vascular cells, myocytes, and fibroblast (157). Kemp and 
colleagues identified 17 miRNAs specific regulated by angio-
tensin II type I receptor (AT1R) activation in VSMCs. Among 
them, miR-483-3p regulates the expression level of four RAAS 
components: angiotensinogen, ACE-1, ACE-2, and AT2R (158). 
Chronic Ang II infusion increased expression levels of miR-132 
and miR-212 in rats heart, aortic wall, and kidney, whereas 
treatment with AT1R blockers decreased their levels in arteries 
of patients subjected to coronary artery bypass grafting (159). 
In ECs, Ang II induced expression of ET-1, a target of miR-155 
and a key regulator in vascular inflammation and remodeling 
(160, 161). Overexpression of miR-155 reduced: (i) Ang 
II-mediated migration and inflammatory activation of ECs (162), 
(ii) AT1R expression in Ang II-treated hypertrophic cardiomyo-
cytes (161), and (iii) Ang II-induced VSMSc proliferation (163).
Endothelium dysfunction is characterized by an imbalance 
in the release of vasodilatative and vasoconstrictive factors. 
Hypertension has been associated with an impairment of 
production of NO, a vasodilator fundamental for the CV 
homeostasis (164). Mounting evidence showed that its bio-
availability could be regulated by miRNAs. Sun and colleagues 
demonstrated that miR-155 decreases NO release through direct 
binding and consequent downregulation of endothelial eNOS 
transcript in HUVEC cells. The authors observed that inflam-
matory stimuli like TNFα may increase the level of miR-155, 
resulting in endothelial dysfunction (165). Another study has 
identified a correlation between a novel polymorphism on the 
solute carrier family 7 member 1 (SLC7A1) gene and the onset of 
essential hypertension (166). The variant allele contains one more 
potential binding site for miR-122 that significantly decreases 
the expression of SLC7A1, leading to a decrease l-arginine and 
NO metabolism and endothelial dysfunction (167). GTP cyclo-
hydrolase 1, essential for the regulation of the eNOS activity, 
is a target of miR-133, which is induced by oxidative stress but 
inhibited by statin (168).
Oxidative stress contributes to the pathogenesis of CVD, 
including hypertension. Elevated ROS can impair vascular, 
renal, and cardiac functions (169). Increased ROS production 
and miR-21 upregulation were found in heart, liver, kidney, and 
aorta of spontaneous hypertensive rats (SHRs) in comparison 
with Wistar control rats. A human study has shown a positive 
correlation between circulating miR-21 levels and hypertensive 
state. However, it has been suggested that miR-21 upregulation is 
part of a compensatory mechanism aimed to decrease ROS level 
in mitochondria. Interestingly, delivery of exogenous miR-21 
lowered BP in the SHR rats, supporting the evidence that miRNAs 
could constitute a potential therapeutic alternative for hyperten-
sion in a near future (170).
Vascular inflammation, together with oxidative stress, is one 
of the principal features of the endothelial dysfunction (171). As 
abovementioned, ET-1 promotes vascular inflammation induc-
ing the expression of Ets-1 transcriptional factor. miR-155 and 
miR-221/222 were able to reduce Ets-1 levels and its downstream 
target. Among them, VCAM-1, MCP-1, and FLT-1 are major 
determinants in leukocytes recruitment (162).
Circulating miRNA in Hypertension
In the last few years, several studies were conducted to compare 
circulating miRNA in hypertensive versus normotensive patients 
in order to find reliable biomarker for this pathology. Different 
studies were performed using high-throughput methodology, 
like genome-wide array-based technique (150). Li et al. compared 
miRNA expression level in 13 hypertensive and 5 control patients. 
Among 27 miRNAs found differentially expressed between the 
two experimental groups, 3 were validated by qPCR in a larger 
cohort. Interestingly, hcmv-miR-UL112, a miRNA encoded by 
the human cytomegalovirus, was upregulated in hypertensive 
patients. The authors suggested that interferon regulatory fac-
tor 1 (IRF-1), target of hcmv-miR-UL112, could be a potential 
regulator of BP (172). Further studies are needed to confirm this 
hypothesis. However, IRF-1 can regulate the expression of AT2R 
and the production of NO in response to inflammatory insult 
(173, 174). In a similar approach, Yang and colleagues have 
screened plasma samples from three independent cohorts 
of patients finding miR-505 increased in hypertension. 
In vitro experiments conducted in miR-505-overexpressing ECs 
underlined its anti-angiogenic effect (175). Another study was 
conducted to identify miRNA signature in peripheral blood and 
exosomes collected from patients exhibiting metabolic risk of 
CVDs, as metabolic syndrome, hypercholesterolemia, hyperten-
sion, and type 2 diabetes. A peculiar expression profile for miR-
130a, -195, and -92a was found to be associated with metabolic 
syndrome and hypertension. Only miR-92a, whose predicted 
target is AT1R, was found in exosomes (176).
Kontaraki and colleagues have published two studies aimed 
to analyze miRNAs expression level in human peripheral blood 
mononuclear cells (PBMCs) using the same cohort of patients 
(with hypertension, n  =  60, controls n  =  29). miR-143/145, 
miR-133a, mir-21, and mir-1 had a distinct expression profile 
in PBMCs collected from hypertensive patients. As mentioned 
before, some of these miRNAs regulate several aspect of VSMCs 
biology, providing further evidence of the fundamental role of 
TABLe 4 | Summarizing table of microRNAs (miRNAs) involved in atherosclerosis.
Tissue miRNA Molecular targets Functions Reference
Liver miR-122 Hmgrc, FAS, SREBP-1 FA and cholesterol homeostasis
Pro-atherogenic
(182–184)
Liver miR-30c Microsomal triglyceride  
transfer protein




Liver miR-128-1, miR-148a, miR-130b, and 
miR-301b
LDL receptor and ABCA1 Lipid metabolism and trafficking
Pro-atherogenic
(187)





Endothelial cells (ECs) miR-10a HOXA1
MAP3K7
Anti-atherogenic (191)
ECs miR-92a Itga5 (Sirt)-1, KFL4-2 Pro-atherogenic (193, 194)
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these molecules in the pathogenesis of essential hypertension 
(177). In addition, the second study showed a lower expression 
level for miR-9 and miR-126 in hypertensive patients in com-
parison to healthy controls (178). Finally, it has been found that 
CD34+ circulating progenitor cells from hypertensive patients 
are characterized by an increased level of miR-221/-222, already 
related to inflammation and oxidative stress (179).
miRNAs iN ATHeROSCLeROSiS
Atherosclerosis is a multistage disease characterized by chronic 
inflammation of the arterial wall, consisting in the progressive 
remodeling of the vessel intima caused by lipoprotein reten-
tion, immune cells recruitment, and endothelial and VSMCs 
dysfunction. Over time, the lesion progresses and results in the 
formation of atherosclerotic plaque, ultimately responsible for 
vessel occlusion and potential thrombotic events. Several studies 
in the last few years provided with a new molecular insight in 
the regulation of atherosclerosis, conferring to miRNAs a pivotal 
role in the regulation of multiple processes related to the plaque 
formation, progression, and potential rupture (summary in 
Table 4) (180).
Cholesterol is an essential component of the cell membrane 
and a precursor of steroid hormones and bile acids. Deregulation 
of cellular and systemic cholesterol levels predisposes to CV and 
metabolic diseases.
In the circulation, cholesterol and triglyceride are carried 
out by lipoprotein complex: low-density lipoproteins (LDLs) 
deliver cholesterol to peripheral tissues, whereas HDLs transport 
cholesterol mostly to the liver or steroidogenic organs, where it is 
metabolized or disposed. Retention of oxidized LDLs (oxLDLs) 
in the subendothelial space drives the accumulation of mac-
rophages that became inflammatory foam cells. High circulating 
LDL levels, together with low circulating HDL, are considered a 
risk factor of atherosclerosis and metabolic disease; miRNAs are 
able to regulate LDL and HDL biogenesis, representing a target 
for future treatment (181).
miR-122 is implicated in the metabolism of hepatic cholesterol 
and fatty acids: in vivo studies have shown that the miR-122 inhi-
bition resulted in decreased total cholesterol plasma levels both 
in mice and non-human primates (182–184).
Microsomal triglyceride transfer protein (MTP) is responsi-
ble for the lipidation of apolipoprotein B with consequent LDL 
production. miR-30c directly binds MTP transcript. Hepatic 
overexpression of this miRNA decreased LDL secretion and 
hyperlipidemia in high fat diet mice and led to reduction of 
atherosclerotic lesions in ApoE−/− mice (185).
In a recent genome-wide association study, almost 200,000 
individuals were screened for single-nucleotide polymorphisms 
(SNPs) associated with abnormal plasma lipid levels. The analysis 
identified 69 miRNAs localized in proximity of SNPs loci already 
correlated with dyslipidemia. Among them, miR-128-1, miR-148a, 
miR-130b, and miR-301b regulate the expression of several 
proteins involved in lipid metabolism and trafficking, such as 
LDL receptor (LDLR), whose activity in the liver is responsible 
for the reuptake and disposal of LDL, and ABCA1, a transporter 
accountable for formation and secretion of HDL (186). Inhibition 
of miR-148a and miR-128-1 produced (i) increased levels of 
expression of LDLR/ABCA1 and augmented LDL clearance in 
C57BL/6J mice and (ii) modulated levels of circulating lipopro-
teins in ApoE−/− mice fed with western diet (187).
ABCA1 has been identified as a target of multiple miRNAs. 
Rayner and colleagues studied the effect of miR-33 downregula-
tion on lipid metabolism and atherosclerosis. miR-33 inhibition 
increased circulating HDL-cholesterol levels and hepatic ABCA1 
expression in both mice and monkeys (188, 189). In addition, 
mice deficient for the LDLR treated with anti-miR-33 showed 
enhanced reverse cholesterol transport in the plasma, liver, and 
feces and a reduction in the atherosclerotic lesion size as well 
as in lipid content. Interestingly, anti-miR-33 was able to enter 
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also in the plaque macrophages, where it caused a reduction 
of inflammatory gene expression and increased reparative M2 
phenotype (188).
Notably, inhibition of miR-33a/b in monkeys resulted in 
a marked suppression of the plasma levels of very low-density 
lipoprotein-associated triglycerides, probably caused by the fatty 
acid synthesis downregulation alongside upregulation of fatty 
acid-oxidation genes (189).
Arterial walls are constantly exposed to hemodynamic forces. 
The vascular endothelium is sensible to mechanical stimuli 
and acts as a transducer, converting stretch and shear stress in 
biochemical activation of the cells in order to maintain vascular 
homeostasis (171). The mechanosensitive miRNAs mainly target 
pathway involved in NO signaling, inflammation, and leukocytes 
recruitment (190). Among them, the anti-atherogenic miR-10a 
and miR-143/45 are increased by laminar flow but decreased by 
disturbed flow (191, 192). In contrast, mirR-92a is downregulated 
by laminar and upregulated by oscillatory shear stress; in  vivo 
studies have shown its expression to be higher in ECs localized 
in atheroprone area. Moreover, inhibition of mir-92a in LDLR−/− 
mice reduced inflammation and atherosclerotic lesions (193, 194).
Atherosclerosis is a chronic inflammatory disease and multi-
ple studies focused on this characteristic. Emerging evidence has 
identified miR-181b as a master regulator of endothelial inflam-
mation. Overexpression of this miRNA was able to decrease 
nuclear NF-κB activation exclusively in ECs, suppressing 
leukocytes recruitment at the atherosclerotic plaque in ApoE−/− 
mice. Notably, miR-181b expression is downregulated following 
inflammatory stimuli, both in vitro (195, 196) and in plasma of 
patients affected by CAD, suggesting that miR-181b loss may 
predispose to development of atherosclerosis (197).
Pro-inflammatory cytokines, such as TNF-α and 
interleukin1-β, also promote the expression of miR-146a, an 
anti-inflammatory miRNA widely expressed in immune cells. 
Recently Ma and colleagues have developed a protocol to deliver 
miR-146a and miR-181b with an E-selectin-targeting multistage 
vector directly to the atherogenic lesion. These nanoparticles 
were able to downregulate chemokines’ expression (CCL2, CCL5, 
CCL8, and CXCL9) and to reduce macrophage recruitment and 
atherosclerotic plaque size in male fed a Western diet apoE−/− 
mice (198).
Several miRNAs are involved in the regulation of macrophage 
inflammatory activity and phenotype, which is fundamental in 
the onset and development of vascular lesions. After adhesion 
to dysfunctional endothelium, monocytes differentiate in mac-
rophages, which play a central role in the lipoprotein uptake 
in the growing plaque, resulting in the creation of a foam cell 
layer. Moreover, macrophages promote a chronic inflammatory 
response secreting a wide range of chemokines and cytokines that 
stimulate the recruitment of other immune cells. Macrophages 
homeostasis in the plaque is also regulated by miR-27a/b, target-
ing genes involved in cholesterol metabolism, like the previously 
discussed ABCA1 (199). Several other miRNAs, including 
miR-302 and miR-26, have shown to increase the formation of 
foam cells inhibiting ABCA1 expression (200, 201).
Macrophages can be classified as M1 (classically activated) or 
M2 (alternatively activated): the first type presents the classical 
pro-inflammatory phenotype, while the latter exhibits an anti-
inflammatory profile. Atherosclerosis lesions are characterized 
by the predominance of M1 macrophages (202). As previously 
mentioned, miR-33 is involved in regulation of lipid metabo-
lism, cholesterol efflux, and inflammatory genes. In addition, 
miR-33-mediated imbalance between aerobic glycolysis and 
mitochondrial oxidative phosphorylation induced M1 mac-
rophage polarization. Moreover, inhibition of miR-33 expression 
in hypercholesterolemic mice resulted in accumulation of M2 
macrophages in the plaque (203).
In addition to macrophages, ECs and VSMCs take part in the 
pathogenesis of atherosclerosis. ECs and VSCMs dysfunction 
has been already extensively discussed in the previous paragraph 
regarding miRNAs in hypertension. In addition, VSMCs are able 
to uptake lipids and transform into macrophage-like foam cells, 
contributing to the progression of the plaque. Recently, Gabunia 
and colleagues have identified miR-133 to be a regulator of VSMC 
foam cell formation, reducing their proliferation and uptake of 
oxLDLs. Thus, miR-133 may represent a therapeutic target for 
vascular inflammatory diseases (204).
Atherosclerosis causes clinical manifestation through vessel 
occlusion or following plaque rupture and thrombotic events. 
Plaque stability is determined by thickness and composition of 
the fibrous cap. miR-145 overexpression induced collagen type 
I and III expression in human aortic VSMCs and promoted the 
acquisition of stable plaque phenotype (205).
miRNA iN ATRiAL FiBRiLLATiON
Atrial fibrillation represents the most common cardiac conduc-
tion disorder, affecting up 2% of the population worldwide (206). 
CV aging, upon which several risk factors may occur, contributes 
to the development of the arrhythmia, thus its prevalence is 
age-related: 70% of affected patients are over 65 years old (207). 
Constituting a documented cause of stroke, AF is an important 
contributor to CV mortality and morbidity in elderly (208). 
Importantly, miRNAs have been shown to play an important role 
in AF initiation and maintenance.
Electrical and structural remodeling constitutes the main 
pathophysiological mechanisms responsible for development 
of AF, which is initiated and maintained by focal ectopic fir-
ing, re-entry circuits, or both conditions simultaneously (209). 
Furthermore, abnormal Ca2+ dynamics and neurohormonal 
dysregulation take part in the making of the conduction disorder 
(210).
Atrial electrical remodeling is mainly caused by alteration in 
ionic currents and modification in ionic channels expression and 
activity. Particularly, the most frequently observed alterations 
regard increases in inward rectifier K+ current (IK1) and reduction 
in inward L-type Ca2+ current (ICaL) (210). A shortening of the 
atrial effective refractory period (ERP), consequent to reduction 
of the action potential duration, and a loss of rate adaptation lead 
to arrhythmogenesis and AF (211). Several miRNAs are impli-
cated in electrical remodeling (Table 5).
Yang and collaborators demonstrated miR-1 to be overex-
pressed in myocardial tissue of CAD patients; its overexpres-
sion, in normal or infarcted rat hearts, has shown to exacerbate 
TABLe 5 | microRNAs (miRNAs) implicated in atrial fibrillation (AF) electrical remodeling.










miR-1 overexpression exacerbates arrhythmogenesis
miR-1 reduction generates increase in IK1 protein Kir2.1
miR-1 upregulation produces reduction of the atrial effective refractory period





miR-328 CACNA1C,  
CACNB1
Tachypaced dogs, miR-328 
transgenic mice
miR-328 overexpression is related to increased vulnerability to AF  
due to reduction in L-type Ca2+ channel density
(217)
miR-499 KCNN3 Permanent AF patients miR-499, upregulated in AF, decreases small-conductance  
calcium-activated potassium channel 3 (SK3)
(218)
miR-26 KCNJ2 Patients with AF, canine,  
and mice AF models
miR-26 knockdown, inhibition, or mutation enhance Kir2.1 expression (219)
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arrhythmogenesis. Furthermore, miR-1 inhibition, with specific 
antisense, suppressed the arrhythmogenic events in the infarcted 
rats (212).
Nevertheless, miR-1 represses GJA1 (encoding connexin 43, 
the gap junction α1 protein) and KCNJ2 (encoding IK1 protein 
Kir2.1), thus its downregulation results in increase in protein 
Kir 2.1 expression, a key factor in AF maintenance (209). In 
electrically tachypaced rabbits, miR-1 upregulation produced a 
reduction of the atrial ERP (213). Lu et al. reported the reduc-
tion of intracellular Ca2+ concentration, induced by miR-1, with 
protective effect against AF (214). Furthermore Terentyev and 
collaborators noticed an improvement in Ca2+ handling related to 
miR-1 downregulation (215). All the reported evidences support 
a key role for miR-1 in cardiac electrical activity regulation.
miR-328, which is related to reduction in L-type Ca2+ 
channel density, is upregulated in AF, contributing to atrial 
electrical remodeling (216). The pro-arrhythmogenic effect of 
miR-328 overexpression was confirmed in dogs and mice models. 
Delivery of antagomiR versus this miRNA was able to revert the 
arrhythmogenic phenotype (217).
Ling and collaborators have proposed atrial miR-499 as a 
further electrical remodeling promoter, due to downregulation 
effect on the KCNN3 gene, which encodes the small-conductance 
calcium-activated potassium channel 3 (SK3). The authors found 
miR-499 to be highly upregulated in AF (218).
Luo and colleagues underlined the role of miR-26 in the 
development of AF, reporting the reduced expression of miR-
26 isoforms in atrial samples of AF animals and patients, and 
the consequent upregulation of IK1/KIR2.1. Particularly, 
adenovirus-mediated expression of miR-26 was related to lower 
AF vulnerability, while opposite effect was produced by endog-
enous miR-26 knockdown in mice (219). This evidence suggests 
the miR-26 to play a protective role in AF. Plasma concentra-
tions of miR-409-3p (a cell proliferator regulator) and miR-432 
(targeting myozenin1) were lower in AF patients than healthy 
ones; Liu and collaborators interestingly noticed that catheter 
ablation of the conduction disorder may restore their levels 
(220). Similarly, in AF individuals, the miRhythm study docu-
mented a reduction of miR-21and an increase of miR-150 after 
ablation; both miRNAs are involved in the regulation of atrial 
remodeling-related genes (221).
miRNAs iN DiABeTeS MeLLiTUS
Diabetes mellitus affects over 400 millions of adults worldwide 
and this number is expected to rise up to more than 550 million 
people by 2030 (222). DM complications are more frequent in 
elderlies compared to their young counterparts (223). While type 
1 diabetes is considered an autoimmune disorder characterized 
by the destruction of the insulin-producing β cells in the pancreas 
by the immune system, type 2 diabetes in a multifactorial disease, 
where genetic predisposition and environmental/lifestyle factors 
result in decreased insulin sensitivity in skeletal muscles, liver, 
and adipose tissue and a progressive reduction in pancreatic 
insulin secretion (224). In both cases, micro- and macro-vascular 
complications represent a major cause of disability and death. The 
former includes diabetic nephropathy, neuropathy, and retinopa-
thy, while the latter refers to the increased risk of ischemic heart 
disease, stroke, and peripheral arterial disease.
microRNAs have been implicated in the pathogenesis of DM 
and they also represent an attractive biomarker in the diagnosis, 
prognosis, and response to treatment in this disease (225).
In 2004, miR-375 was identified as a pancreatic islet-specific 
miRNA regulating insulin secretion, through its target myotro-
phin (Mtpn), a transcription activator of NF-κB; moreover, the 
inhibition of miR-375 function resulted in enhanced insulin secre-
tion (226). In further studies on insulinoma cells and primary rat 
islets, miR-375 was found to directly target 3′-phosphoinositide-
dependent protein kinase-1, a key molecule in PI 3-kinase signal-
ing in pancreatic β-cells, suggesting that miR-375 is involved in 
glucose regulation of insulin gene expression and β-cell growth 
(227). Furthermore, in mice lacking miR-375, pancreatic β-cells 
are decreased, while genetic deletion of miR-375 from obese 
mice (ob/ob), reduced the proliferative capacity of the endocrine 
pancreas and resulted in a severely diabetic state. Bioinformatic 
analysis has also shown that miR-375 regulates genes involved in 
cellular growth and proliferation (228). Moreover, it seems that 
antagonizing miR-375 may enhance the effects of exendin-4 in 
DM patients (229).
Another target of miR-124 is Mtpn, which was found to be 
overexpressed in DM human pancreatic islets, resulting in an 
impaired glucose-induced insulin secretion (230). Moreover, 
miR-124a silencing was associated with increased expression 
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of predicted target genes (as Mtpn) involved in β-cell function, 
suggesting that an altered miR-124a expression may contribute 
to β-cell alteration (231).
In the regulation of insulin secretion, a role seems to be played 
by miR-29a and -29b through the silencing of monocarboxylate 
transporter in β-cells (232); moreover, this family of miRNAs is 
implicated in the development of insulin resistance in myocytes, 
through the repression of the insulin receptor substrate 1 (IRS-1), 
a key molecule in the insulin signaling (233). Other indirect regu-
lators of IRS-1 are miR-103 and -107, whose expression is upregu-
lated in obese mice. Silencing of miR-103/107 leads to improved 
glucose homeostasis and insulin sensitivity, whereas gain of 
miR-103/107 function in liver or adipose tissue impairs glucose 
homeostasis (234). The target of miR-103/107 is caveolin-1, 
which is a stabilizer of the interaction between IRS-1 and caveolae 
(235). Several other miRNAs are involved in the pathogenesis of 
DM, affecting pancreatic β-cell function and insulin resistance, as 
miR-143, -122, and the let-7 family but further studies are needed 
to address their potential as therapeutic targets.
Circulating miRNAs in Diabetes Mellitus
Circulating miRNAs have been proposed as useful biomarkers in 
the diagnosis, complications risk, and therapeutic management 
in DM.
Zampetaki et  al. analyzed plasma miRNA levels from the 
Bruneck study population, finding a loss of endothelial miR-
126 and other miRNAs in type 2 DM, even before the clinical 
manifestation of the disease (236). Another study analyzed 
the expression of diabetes-related serum miRNAs (miR-9, 
miR-29a, miR-30d, miR-34a, miR-124a, miR-146a, and miR-
375) in patients with newly diagnosed DM, impaired glucose 
tolerance and healthy controls, demonstrating all seven miR-
NAs to be significantly upregulated in DM and miR-34 has 
shown the most significant differences (237). In another study 
in a Chinese population, plasma miR-126 was significantly 
reduced in susceptible individuals and DM patients compared 
to normal individuals, suggesting that it may serve as a potential 
biomarker for early identification of individuals susceptible 
to DM (238). More recently, another study has indicated that 
plasma levels of miR-1249, miR-320b, and miR-572 might help 
differentiating patients with prediabetes and newly diagnosed 
type 2 DM (239).
In the evaluation of disease progression, a recent study has 
demonstrated that nephropatic diabetic progressor patients 
showed significantly greater serum levels of miR-21, miR-29a, 
miR-29b, and miR-29c in comparison with non-progressors 
implying the potential usefulness of those miRNAs in monitoring 
diabetic nephropathy progression (240). Another recent study 
has shown that circulating endothelium-enriched miR-126 is 
associated with CAD in DM patients (241).
Other studies in patients with type 1 DM have suggested 
serum miR-25 levels to be associated with residual β-cell func-
tion and glycemic control during disease progression (242); 
in another type 1 DM cohort, circulating levels of miR-21 and 
miR-210 were significantly upregulated in plasma and urine of 
these patients, while urinary miR-126 levels were significantly 
lower, compared to controls (243). In PBMCs from patients with 
type 1 DM, it has been demonstrated that miR-21a and miR-93 
levels are downregulated compared to controls (244).
Circulating miRNAs in DM might be valuable biomarkers in 
the diagnosis and identification of the subgroups of patients at 
higher risk of complications. However, larger studies are needed 
to establish their potential.
SUMMARY AND CHALLeNGiNG ASPeCTS
Aging is a complex phenomenon involving different systems and 
usually associated with several comorbidities. miRNAs are key 
regulators of CV pathophysiology targeting multiple biological 
pathways. In our review, we have described specific miRNAs 
involved or altered in CV aging and age-related pathologies. 
However, due to an expected publication bias, it is difficult to cite 
failing studies and make a really balanced evaluation. Indeed, 
the possibility that miRNA studies with negative results were not 
published at all cannot be excluded.
In this paragraph, we have summarized the main involved 
miRNAs. Cardiac miR-21 shows a profibrotic role in both HF 
and aging heart while miR-22 exercises a pro-hypertrophy 
effect in HF and accelerates fibroblast migration during cardiac 
aging (51, 52, 110, 125). Hence, miR-21 and miR-22 seem to 
be a valuable target for elderly patients with HF. In addition, 
circulating miR-21 levels are increased in older people as well 
as in patients with HF, hypertension, diabetes, and cancer (50, 
97, 98, 177, 243). miR-22 inhibition was able to rescue post-MI 
cardiac dysfunction in old mice, but not in young ones (56). 
miR-29 is not an appealing target in old patients with HF since 
its overexpression could counteract post-MI remodeling but 
also otherwise sensitize the aorta to the formation of aneurysms 
(a common phenomenon during aging) (74, 130). Elderly 
patients are usually affected by atherosclerosis and hypertension 
(66). The inhibition of miR-122 could constitute a good option 
for these patients since miR-122 upregulation leads to athero-
genesis and endothelial dysfunction (166, 182, 183). miR-181 
is downregulated during aging, HF, CAD, and hypertension, 
suggesting that miR-181 loss is detrimental for CV system (94, 
153, 197).
Several circulating biomarkers are now clinically available 
for diagnosis, prognosis, or guide for treatment of different age-
related CVDs (245–247). Moreover, numerous biomarkers of 
human aging have been studied but, to date, no one has shown 
consistency in different settings and populations. Some authors 
tried to evaluate a combination of different biomarkers in order to 
take in account age-related modifications in different systems and 
pathways (e.g., inflammation or endocrine and renal function) 
(248, 249). Unfortunately, we are far away to identify circulating 
biomarker patterns that stratify the risk of morbidity and mortality 
for elderly patients with CV diseases. At this regard, since several 
circulating miRNAs are altered in CV aging per se and in different 
age-related diseases (see above), we strongly believe that a specific 
combination of few circulating miRNAs would be an effective 
biosignature panel of CV aging (88, 89). Recently, Navickas 
et  al. systematically reviewed 19 studies and found that miR-1, 
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miR-133a/b, miR-145, miR-208a/b, and miR-499 are the most 
promising biomarkers for diagnosis and prognosis of CVDs (250).
However, to effectively establish circulating miRNAs as bio-
marker in clinical practice, developing a standardized method 
for blood collection as well as miRNAs extraction, detection, 
and normalization is essential (251, 252). In fact, it is crucial 
to set the extraction protocol and the storage of blood samples 
(252–254). Reverse transcription quantitative real-time PCR is 
the most extensively used method for miRNA profiling while it 
is still unclear what is the best strategy for data normalization 
(255–257). Since numerous studies have been performing on this 
area, we are confident that researchers will be able to standardize 
the analysis of circulating miRNAs, in a near future (258, 259). 
Importantly, an internationally validated method will decrease 
currently elevated costs, allow routinely miRNA identification in 
research/hospital lab, and regulate ethical aspects.
APPLiCATiONS AND FUTURe 
DiReCTiONS
In vitro and animal as well as clinical sample-based studies on 
miRNAs have been helping to understand the development and 
the progression of age-related CVDs. The potential of miRNAs 
is evidenced by the increased number of patent applications 
submitted in the last years (260, 261). miRNA-based treatment 
is a multi-target therapy resulting in simultaneous regulation of 
crucial pathways and making it an excellent candidate to modu-
late complex networks. However, the challenge (at least in part 
already solved) consists in potential off-target effects, delivery 
system issues, and safety. Interesting data have been recently pub-
lished showing the safety and efficacy of miRNA-based therapies 
in clinical trials. Mimic-therapy for miR-29b, a miRNA involved 
in fibrous scar formation in the skin, is ongoing phase 1 clinical 
study in order to evaluate safety and tolerability in healthy volun-
teers subjected to intradermal injection of the drug.1 Importantly, 
the first antagomiR (miravirsen, anti-miR-122) has been success-
fully tested in a phase-II trial for the treatment of patients with 
hepatitis C virus infection (262). Data indicated that miravirsen 
(as four-week monotherapy) offers long-term suppression of 
viremia and shows both safety and efficacy. Other clinical trials 
using antagomiR are ongoing: anti-miR-155 in patients suffering 
from cutaneous T-cell lymphoma (see text footnote 1) and anti-
miR-103/107 for the treatment of non-alcoholic steatohepatitis in 
patients with type 2 diabetes/prediabetes.2
1 http://www.miragentherapeutics.com/clinical-trials/.
2 www.Regulusrx.com.
Although miRNA-based therapy to treat CVDs is still in the 
preclinical phase (small- and large-animal models), the promis-
ing advancements in other areas support the great enthusiasm for 
testing miRNA therapeutics as a new class of drugs for age-related 
CVDs in the next future. RG-012, a single-stranded, chemically 
modified oligonucleotide that binds to and inhibits the function 
of miR-21 has currently been tested in phase I clinical trial for 
Alport syndrome (see text footnote 2). Since the well-established 
profibrotic role of miR-21 in cardiac tissue, RG-012 could repre-
sent a potential therapy for aged heart. miR-34a, involved in both 
cardiac and vascular aging, is another promising target to design 
therapeutics to fight CV aging (58, 62, 68, 263). It has been shown 
that the inhibition of three miR-34 family members (miR-34a, 
-34b, and -34c) attenuates cardiac dysfunction in mouse models 
of HF (92). Furthermore, miR-34c is elevated in the hippocampus 
of patient as well as mouse models of Alzheimer disease so it 
has been identified as a potential therapeutic target (91). Taken 
together, these results suggest the intriguing possibility to inhibit 
the miR34 family members in elderly patients suffering dementia 
and HF.
Latest technological improvements in terms of miRNA bio-
availability and stability are definitely encouraging, though the 
tissue specificity and off-target side effects still remain issues to 
work on. However, the development of effective delivery systems, 
further studies on large-animal models and clinical trials are 
required to demonstrate the real application of miRNA-based 
treatments for age-related CVDs in clinical practice.
One of the major challenges in geriatric medicine is to find 
reliable biomarkers for diagnosis, prognosis, or prediction of the 
response to specific drugs. miRNAs represent a very promising 
tool due to their stability in the circulation and unique signature 
in CVDs. Detection of multiple miRNAs appears to improve the 
predictive power compared to single miRNAs.
Despite several publications identified miRNA as a remarkable 
target for diagnosis and treatment of age-related CVDs, further 
studies are needed to investigate their translational potential in 
the real clinical practice.
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